Vigonvita (Lianyungang) Pharmaceutical Co., Ltd. (referred to as the “Lianyungang Facility”) is located within the China Medical Valley at the Lianyungang National-level Development Zone. The site occupies 200 mu (approximately 13.3 hectares), with a currently completed construction area of 51,955 square meters.

The Lianyungang Facility has established an active pharmaceutical ingredient (API) and drug product manufacturing system that complies with both domestic and international Good Manufacturing Practice (GMP) standards and Environment, Health, and Safety (EHS) requirements. This includes a multifunctional, modular emergency production platform capable of sustaining routine drug production while allowing for rapid production line adjustments during emergencies. This setup provides robust support for the research, development, translation, and supply of pharmaceuticals to address emerging and re-emerging viral infections.

The Lianyungang Facility has successfully obtained Drug Manufacturing License Type A, C, and D certificates. This comprehensive licensing enables end-to-end service capabilities from R&D translation to commercial-scale production, facilitating the rapid industrialization of new drugs and ensuring reliable commercial supply.